Cargando…
Prediction of RECRUITment In randomized clinical Trials (RECRUIT-IT)—rationale and design for an international collaborative study
BACKGROUND: Poor recruitment of patients is the predominant reason for early termination of randomized clinical trials (RCTs). Systematic empirical investigations and validation studies of existing recruitment models, however, are lacking. We aim to provide evidence-based guidance on how to predict...
Autores principales: | Kasenda, Benjamin, Liu, Junhao, Jiang, Yu, Gajewski, Byron, Wu, Cen, von Elm, Erik, Schandelmaier, Stefan, Moffa, Giusi, Trelle, Sven, Schmitt, Andreas Michael, Herbrand, Amanda K., Gloy, Viktoria, Speich, Benjamin, Hopewell, Sally, Hemkens, Lars G., Sluka, Constantin, McGill, Kris, Meade, Maureen, Cook, Deborah, Lamontagne, Francois, Tréluyer, Jean-Marc, Haidich, Anna-Bettina, Ioannidis, John P. A., Treweek, Shaun, Briel, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441612/ https://www.ncbi.nlm.nih.gov/pubmed/32825846 http://dx.doi.org/10.1186/s13063-020-04666-8 |
Ejemplares similares
-
Comparison of randomized controlled trials discontinued or revised for poor recruitment and completed trials with the same research question: a matched qualitative study
por: Briel, Matthias, et al.
Publicado: (2019) -
Reporting Quality of Journal Abstracts for Surgical Randomized Controlled Trials Before and After the Implementation of the CONSORT Extension for Abstracts
por: Speich, Benjamin, et al.
Publicado: (2019) -
Characteristics and survival of patients with cancer with intended off-label use—a cohort study
por: Schmitt, Andreas Michael, et al.
Publicado: (2022) -
Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey
por: Schandelmaier, Stefan, et al.
Publicado: (2020) -
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
por: Herbrand, Amanda Katherina, et al.
Publicado: (2021)